SecBot SecBot
SECBOTREPLAY Home › Report › REGN

REGN · Regeneron won a significant motion in its patent infringement…

REGENERON PHARMACEUTICALS, INC. · COURT-RULING filed Jul 6, 2026 at 20:00 ET

At the news

BULLISHIMPACT 6/10

COURT-RULING filed Jul 6, 2026 at 20:00 ET

Regeneron won a significant motion in its patent infringement litigation against Amgen, with the court striking Amgen's inequitable conduct, patent misuse, and unclean hands defenses and dismissing related counterclaims with prejudice, and dismissing antitrust/UCL counterclaims with prejudice as to the '099 patent. The laches defense and counterclaim survive, preserving some uncertainty, but the ruling substantially narrows the case and removes high-risk claims that could have threatened enforceability of Regeneron's Eylea patents.

  • Court struck Amgen's inequitable conduct defense/counterclaim with prejudice (Thirteenth Additional Defense and Fourth Counterclaim)
  • Court struck Amgen's patent misuse defense/counterclaim with prejudice (Fourteenth Additional Defense and Fifth Counterclaim)
  • Court struck Amgen's unclean hands defense with prejudice (Fourth Additional Defense)
  • Court dismissed Amgen's antitrust counterclaims with prejudice as to the '099 patent and without prejudice as to the 2024 Litigation Patents

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access